Wilms Tumor 1 Gene Mutations Are Associated With a Higher Risk of Recurrence in Young Adults With Acute Myeloid Leukemia: A Study From the Acute Leukemia French Association.

The article reports on the study that examines patients with acute myeloid leukemia (AML) who were treated on the Acute Leukemia French Association 9802 trial. It identifies wilms tumor 1 (WT1) mutations in 5% of patients, and no mutation was detected in patients who had favorable cytogenetics. It suggests that WT1 mutations represent an adverse prognostic factor in young adults with AML.